Ftse Mib
38.524,40
1,38%
DAX
23.036,56
2,23%
S&P 500
5.521,52
-1,39%
NASDAQ
17.303,01
0,00%
Bitcoin
83.389,70
2,90%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Xenon Pharmaceuticals Inc (XENE) Xenon Pharmaceuticals Inc (XENE) Notizie

Xenon Pharmaceuticals Inc

XENE
35,18
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 12:00:03
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/3/202500:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/3/202500:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/3/202500:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/3/202521:01GLOBEXenon to Present at Stifel 2025 Virtual CNS Forum
05/3/202522:25EDGAR2Form 8-K - Current report
27/2/202523:28EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202522:39EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202522:04EDGAR2Form 8-K - Current report
27/2/202522:01GLOBEXenon Reports Fourth Quarter & Full Year 2024 Financial..
25/2/202522:01GLOBEXenon to Present at the 45th Annual TD Cowen Healthcare..
20/2/202522:01GLOBEXenon to Report Q4 and Full Year 2024 Financial Results on..
28/1/202502:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/1/202502:25EDGAR2Form 144 - Report of proposed sale of securities
24/1/202523:13EDGAR2Form 144 - Report of proposed sale of securities
24/1/202500:34EDGAR2Form 144 - Report of proposed sale of securities
17/1/202515:01EDGAR2Form 8-K - Current report
13/1/202514:30GLOBEXenon Outlines Key Corporate Milestone Opportunities for..
07/1/202514:30GLOBEXenon to Present at the 43rd Annual J.P. Morgan Healthcare..
20/12/202400:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202423:50EDGAR2Form 144 - Report of proposed sale of securities
06/12/202422:01GLOBEXenon Showcases New Long-Term Azetukalner Data from X-TOLE..
25/11/202414:30GLOBEXenon to Showcase New Long-Term Azetukalner Data at AES 2024
13/11/202422:01GLOBEXenon to Present at Upcoming Investor Conferences
12/11/202422:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202422:09EDGAR2Form 8-K - Current report
12/11/202422:01GLOBEXenon Reports Q3 2024 Financial Results and Business Update
05/11/202422:01GLOBEXenon to Report Q3 2024 Financial Results on November 12,..
02/10/202422:28GLOBEXenon to Present at BofA Securities 2024 CNS Therapeutics..
09/9/202414:30GLOBEXenon Showcases Azetukalner Data at 15th European Epilepsy..
12/8/202414:30GLOBEXenon Expands Leadership Team with Matthew D. Ronsheim,..
09/8/202422:57EDGAR2Form S-3ASR - Automatic shelf registration statement of..
08/8/202422:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202422:08EDGAR2Form 8-K - Current report
08/8/202422:01GLOBEXenon Reports Q2 2024 Financial Results and Business Update
01/8/202422:01GLOBEXenon to Report Q2 2024 Financial Results on August 8, 2024
13/7/202403:44EDGAR2Form 144 - Report of proposed sale of securities
12/6/202423:32EDGAR2Form 144 - Report of proposed sale of securities
05/6/202423:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202423:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202423:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202423:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202423:30EDGAR2Form 144 - Report of proposed sale of securities
05/6/202422:22EDGAR2Form S-8 - Securities to be offered to employees in employee..
05/6/202422:12EDGAR2Form 8-K - Current report
05/6/202422:01GLOBEXenon Pharmaceuticals to Present at the Goldman Sachs 45th..
28/5/202414:30GLOBEXenon Pharmaceuticals Presents Data from Phase 2 X-NOVA..
09/5/202422:35EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:09EDGAR2Form 8-K - Current report
09/5/202422:01GLOBEXenon Pharmaceuticals Reports First Quarter 2024 Financial..
08/5/202422:01GLOBEXenon Pharmaceuticals to Present at the BofA Securities..
Apertura: Min: Max:
Chiusura: 35,18

La tua Cronologia

NASDAQ
XENE
Xenon Pharmaceuticals
DOWI
DJUSCX
DJ US Specialty Chemicals
USOTC
TKKEF
Tokyotokeiba (PK)
USOTC
ZFSVF
Zurich Financial Services (QX)
USOTC
AUTLF
Austal (PK)
USOTC
TSEQF
Tosei Reit Investment (PK)
COIN
BAXUSD
BABB
USOTC
TCHBF
Tecan ag Hombrechtikon N... (PK)
DBI
4N65
DAXsubsector All Househo...
USOTC
ATCMF
Atico Mining (QX)
USOTC
CBLRF
Campbell Resources (CE)
NASDAQ
SMCX
Defiance Daily Target 2X...
UNSW
OCCETH
Ocam.Fi
USOTC
TKMJF
Telkom (PK)
LSE
MMAG
Musicmagpie
USOTC
TNGCF
Tongcheng Travel (PK)
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci